RxDoctor Payments DataLook up a doctor →

Deepika Shah, MD

Ophthalmology · Chevy Chase, MDNPI 1316172489

Payments from drug & device makers

$141,950in general payments, 2019–2025

Across 487 payments — averaging $291.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$58K
  • Sun Pharmaceutical Industries Inc.$45K
  • Novartis$20K
  • Biotissue Holdings Inc.$12K
  • Kala Pharmaceuticals, Inc.$1K
  • Alcon$594
  • plus $5K from 19 others

What the payments were for

  • Consulting fees$7,1856%
  • Speaking & faculty fees$91,90075%
  • Travel & lodging$10,9289%
  • Food & beverage$12,46810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$141,950 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$412,583
Medicare patients
694
Services billed
4,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine166$217,708
XiidraLifitegrast60$87,448
MieboPerfluorohexyloctane/Pf82$73,153
CequaCyclosporine56$58,184
Cyclosporine72$41,829
TyrvayaVarenicline Tartrate27$26,107
Loteprednol Etabonate45$8,177
LumiganBimatoprost12$5,648
LotemaxLoteprednol Etabonate18$5,542
Travoprost19$3,348
Brimonidine Tartrate19$2,918
Prednisolone Acetate49$2,432
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$2,072
Difluprednate13$1,437
Latanoprost76$913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$378$223,356178 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$57,978$160,600142 claims
Sun Pharmaceutical Industries Inc.Cequa$44,869$58,18456 claims
Oyster Point Pharma, Inc.Tyrvaya$592$26,10727 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax$186$13,71863 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →